Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Additions to Abcodia

Premium

Cancer biomarker developer Abcodia has appointed Mike Fisher to be director of business development and Steve Pereira as a specialist advisor.

Fisher, who will lead the firm's commercial activities, formerly was business development director at Bio Nano Consulting and a senior advisor to the UK government and the North American UK Trade and Investment Network for the Life Science Industry.

Pereira, who will advise the company on developing biomarkers for early diagnosis and screening of pancreatic cancer, is a consultant gastroenterologist at several hospitals in London and is chairman of the British Society of Gastroenterology's Pancreatic Section.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.